Pharmaceuticals 2011, 4(3), 485-493; doi:10.3390/ph4030485

Neuropeptide Receptors: Novel Targets for HIV/AIDS Therapeutics

Received: 3 February 2011; in revised form: 4 March 2011 / Accepted: 7 March 2011 / Published: 9 March 2011
(This article belongs to the Special Issue GPCR Based Drug Discovery)
View Full-Text   |   Download PDF [236 KB, uploaded 9 March 2011]
Abstract: The vasoactive intestinal peptide/pituitary adenylyl cyclase-activating polypepetide (VPAC) receptors are important for many physiologic functions, including glucose homeostasis, neuroprotection, memory, gut function, modulation of the immune system and circadian function. In addition, VPAC receptors have been shown to function in vitro to modulate the infection of HIV by a signal transduction pathway that appears to regulate viral integration. In this article, the affects of VPAC stimulation on HIV infection will be reviewed and approaches for the development of HIV/AIDS therapeutics that target these receptors will be described. Novel HIV/AIDS therapeutics are urgently required to stem the continued spread of this disease, particularly in underdeveloped countries. Drug design to inhibit signaling through VPAC1 and stimulate signaling through VPAC2 could lead to alternative therapies for the treatment and/or prevention of HIV/AIDS.
Keywords: neuropeptide receptors; HIV/AIDS; VPAC1; VPAC2; HIV therapeutics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Branch, D.R. Neuropeptide Receptors: Novel Targets for HIV/AIDS Therapeutics. Pharmaceuticals 2011, 4, 485-493.

AMA Style

Branch DR. Neuropeptide Receptors: Novel Targets for HIV/AIDS Therapeutics. Pharmaceuticals. 2011; 4(3):485-493.

Chicago/Turabian Style

Branch, Donald R. 2011. "Neuropeptide Receptors: Novel Targets for HIV/AIDS Therapeutics." Pharmaceuticals 4, no. 3: 485-493.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert